Earlier, Clearer, Detection of Nephrotoxicity

Nephrotoxicity is an important issue in drug development but current tests of renal injury, e.g. serum creatinine or proteinuria, are late biomarkers and provide little mechanistic information.

CLICK HERE FOR THE CRO GUIDE TO BIOTRIN'S KIDNEY SAFETY BIOMARKERS

Used on a daily basis by the World’s leading pharmaceutical companies and CROs, the Biotrin Acute Kidney Injury Test panel offers a unique opportunity to detect and localize renal effects to distinct parts of the nephron. This increased sensitivity and specificity enables renal injuries to be detected earlier and provides increased detail regarding pathology and time course.

• Biotrin Urinary Alpha GST EIA: Detection of proximal tubular effects.

• Biotrin Pi GST EIA: Detection of distal tubular effects.

The Biotrin Acute Kidney Injury Test panel has been successfully used to study renal effects in:

• Phase I clinical trials
• Nephrotoxicity
• Diabetes
• Surgical studies
• Human
• Animal
• In-vitro studies

The Biotrin Acute Renal Injury Test panel: Whenever precise, accurate data on renal effects is required.